Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 19/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 14/20 | 0.69 |
| ▸ | CHRM1 | P11229 | 14/20 | 0.69 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.45 |
| ▸ | TACR1 | P25103 | 2/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.45 |
| ▸ | HRH1 | P35367 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | RGS12 | O14924 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2821074 | 0.94 | CHRM3 (0.77) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trifluoroacetic Acid SCHEMBL2819774 | 0.84 | CHRM3 (0.61) | CHRM3CHRM2CHRM1 | |
| Trifluoroacetic Acid SCHEMBL2818934 | 0.84 | CHRM3 (0.75) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trifluoroacetic Acid SCHEMBL2823069 | 0.83 | CHRM3 (0.56) | CHRM3CHRM2CHRM1RGS12 | |
| Trifluoroacetic Acid SCHEMBL2827207 | 0.83 | CHRM3 (0.63) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trifluoroacetic Acid SCHEMBL2819788 | 0.82 | CHRM3 (0.69) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL2823707 | 0.82 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL2821963 | 0.81 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Bromide SCHEMBL2823063 | 0.81 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trifluoroacetic Acid SCHEMBL2822239 | 0.80 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1519933-B1 | QUINUCLIDINE AMIDE DERIVATIVES | ALMIRALL SA (ES) | 2010-05-12 | — | — | EP | claimed |
| US-7488735-B2 | antagonists of M3 muscarinic receptors; N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-hydroxy-2,2-dithien-2-ylacetamide; respiratory disorders, urological disorders, gastrointestinal disorders, cardiovascular disorders; alkylation | LABORATORIOS ALMIRALL S.A. (ES) | 2009-02-10 | — | — | US | claimed |
| US-20080234316-A1 | Quinuclidine Amide Derivatives | ALMIRALL AG | 2008-09-25 | — | — | US | claimed |
| US-20060167042-A1 | antagonists of M3 muscarinic receptors; N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-hydroxy-2,2-dithien-2-ylacetamide; respiratory disorders, urological disorders, gastrointestinal disorders, cardiovascular disorders; alkylation | LABORATORIOS ALMIRALL S.A. (ES) | 2006-07-27 | — | — | US | claimed |
| US-7718670-B2 | Quinuclidine amide derivatives | LABORATORIOS ALMIRALL S.A (ES) | 2010-05-18 | — | — | US | disclosed |
| EP-1519933-B1 | QUINUCLIDINE AMIDE DERIVATIVES | ALMIRALL SA (ES) | 2010-05-12 | — | — | EP | disclosed |
| US-7488735-B2 | antagonists of M3 muscarinic receptors; N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-hydroxy-2,2-dithien-2-ylacetamide; respiratory disorders, urological disorders, gastrointestinal disorders, cardiovascular disorders; alkylation | LABORATORIOS ALMIRALL S.A. (ES) | 2009-02-10 | — | — | US | disclosed |
| US-20080234316-A1 | Quinuclidine Amide Derivatives | ALMIRALL AG | 2008-09-25 | — | — | US | disclosed |
| US-20060167042-A1 | antagonists of M3 muscarinic receptors; N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-hydroxy-2,2-dithien-2-ylacetamide; respiratory disorders, urological disorders, gastrointestinal disorders, cardiovascular disorders; alkylation | LABORATORIOS ALMIRALL S.A. (ES) | 2006-07-27 | — | — | US | disclosed |
| EP-1519933-A1 | QUINUCLIDINE AMIDE DERIVATIVES | Almirall Prodesfarma AG (CH) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004005285-A1 | NEW QUINUCLIDINE AMIDE DERIVATIVES | ALMIRALL PRODESFARMA AG (CH) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234316-A1 | Quinuclidine Amide Derivatives | CHRM3, CHRM2, CHRM1 | CHRM3 1/4885CHRM2 2/4885CHRM1 3/4885 |
| US-20060167042-A1 | antagonists of M3 muscarinic receptors; N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-hydroxy-2,2-dithien-2-ylacetamide; respiratory disorders, urological disorders, gastrointestinal disorders, cardiovascular disorders; alkylation | CHRM3, CHRM2, CHRM1 | CHRM3 1/4885CHRM2 2/4885CHRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.